While rare, theres also a risk of developing more serious side effects, including pancreatitis, kidney damage, gallbladder disorders, or a bowel obstruction
And I apologize, I should not just assume that you've been listening to the Dr
Lillys Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease
These combined mechanisms underpin their efficacy for both weight reduction and cardiometabolic protection ( In recent years, the remarkable efficacy of tirzepatide, a dual GIP/GLP-1 receptor agonist, has emerged ( However, these benefits are accompanied by concerns about side effects, cost, long-term sustainability and, above all, the loss of lean mass, which may be mitigated by concurrent exercise ( Exercise and lifestyle interventions remain foundational for obesity and metabolic disease management, offering broad health benefits, but are often limited by adherence and modest long-term weight loss ( Recent randomized controlled trials and meta-analyses suggest that combining GLP-1RAs with exercise may yield additive or synergistic effects on weight loss and metabolic syndrome severity as well as on oxidative stress and inflammation
Most patients stay on treatment for at least 6 months to reach the target weight
In this blog post, we'll guide you through the available savings programs for popular weight loss medications like Wegovy, Zepbound, Mounjaro, Ozempic, Rybelsus, Victoza, and Saxenda
